Patient Reported Outcomes of New Brand-Generic Product of Teriflunomide in Patients with Relapsing-Remitting Multiple Sclerosis: Preliminary Analysis

1Roya Abolfazli, 2Seyed Massood Nabavi, 3Amirereza Azimi, 4Mohammadali Nahayati, 5Koroush Gharegozli, 6Monireh Ghazaeian, 7Hamid Reza Torabi, 8Shahrzad Shahrokhi, 1Sara Samadzadeh 1Tehran University of Medical Sciences – Amiralam Hospital, Department of Neurology, Tehran, Iran; 2Shahed University of Medical Sciences, Department of Neurology, Tehran, Iran; 3Tehran University of Medical Sciences, Sina Hospital, Multiple Sclerosis Research Center, Tehran,…

Long-Term Efficacy for Patients Receiving Cladribine Tablets in CLARITY/CLARITY Extension: Primary Results from 9–15 Years of Follow-Up in the CLASSIC-MS Study

1Gavin Giovannoni, 2Thomas Leist, 3Aida Aydemir, 3Elisabetta Verdun Di Cantogno 1Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; 2Division of Clinical Neuroimmunology, Jefferson University, Philadelphia, United States; 3EMD Serono Research & Development Institute, Inc. (an affiliate of Merck KGaA), Billerica, United States Background: CLASSIC-MS…

Pregnancy Outcomes in Patients with Multiple Sclerosis Following Exposure to Ofatumumab

1Bassem Yamout, 2Kerstin Hellwig, 3Riley Bove, 4Pranava Katkuri, 5Ulf Schulze Topphoff, 6Dee Stoneman, 7Ronald Zielman, 8Ratnakar Pingili, 9Maria K. Houtchens 1Neurology Institute and Multiple Sclerosis Center, Harley Street Medical Centre, Abu Dhabi, UAE; 2Department of Neurology, St Josef Hospital, Ruhr University, Bochum, Germany; 3University of California San Francisco, San Francisco, CA, USA; 4Novartis Pharmaceuticals Pvt.…

Epidemiology of COVID-19 in Patients with MS: A Hospital-Based Registry

1Sharareh Eskandarieh, 1Mohammad Ali Sahraian, 1Vahid Shaygannejad, 1Abdorreza Naser Moghadasi, 1Fereshteh Ashtari, 1Hamidreza Ghalyanchi, 1Seyed Mohammad Baghbanian, 1Hossein Mozhdehipanah, 1Nastaran Majdinasab, 1Samaneh Houseini, 1Maryam Poursadeghfard, 1Nahid Beladimoghadam, 1Nazanin Razazian , 1Zhila Maghbooli 1Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran Background: Recent Covid-19 outbreak around the world turned into an international public health concern.…

Variables Affecting Disease Modifying Therapy Adherence and Impact of Adherence on Multiple Sclerosis Patients (Egyptian Experience)

1Amr Abdelsalam, 2Rasha Elkabany, 2Ibrahim Alahmar, 2Mona Sabry 1Nasser institute for research and treatment, Cairo, Egypt; 2Menoufia University, Menoufia, Egypt Objective(s): To realize the degree of DMT adherence among MS patients in Egypt. To find the barriers contributing to medication adherence. To evaluate the clinical impact of non-adherence on MS patients. Material(s) and Method(s): This…

The Effect of Rituximab on Mood Disorders in Multiple Sclerosis

1Maryam Poursadeghfard, 1Mozhgan Sattar, 1Mahnaz Bayat 1Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran Background: Mood disorders are the most concurrent problems in multiple sclerosis (MS) that have a great influence on the quality of life of these patients. Objective(s): Disease-modifying drugs (DMDs) could have some positive or negative psychological effects. Rituximab…

Claims-Based Relapse and Hospitalization Rates in Patients with Multiple Sclerosis Treated with Natalizumab or Ocrelizumab

1Jacqueline Nicholas, 2Nick Belviso, 2Geentanjoli Banerjee, 2Caroline Geremakis, 2Robin Avila, 2Karthik Bodhinathan 1OhioHealth MS Center, Riverside Methodist Hospital, Columbus, United States; 2Biogen, Cambridge, United States Background: Natalizumab (NTZ) and ocrelizumab (OCR) are high-efficacy disease-modifying therapies (DMTs) approved to treat relapsing forms of multiple sclerosis (MS). Real-world head-to-head data comparing relapses and related hospitalization rates for…

Treatment of Progressive Multifocal Leukoencephalopathy with Pembrolizumab

1Yousef Saleh Aldughaythir, 1Mazen Sulaiman Alamr 1King Fahad Medical City, Riyadh, Saudi Arabia Background: Progressive multifocal leukoencephalopathy (PML) is a fatal, rare viral infection of the brain that leads to demyelination and neuronal loss. It develops almost exclusively in patients with a compromised cell-mediated immunity with conditions like acquired immunodeficiency syndrome, hematologic malignancies and treatment…

Economic Analysis for Introduction of Cladribine Tablets as a Treatment for Relapsing Multiple Sclerosis Patients with High Disease Activity in Kuwait

1Raed Alroughani, 2Samar Farouk Ahmed, 3Amr Abokoura, 4Essam Alsultan, 5Amir Boshra, 5Rawan Alcharif, 6Rita Ojeil, 7Sujata Basu 1Department of Medicine, Amiri Hospital, Sharq, Kuwait, Neurology Department, 2Neurology Department, Ibn Sina Hospital, Kuwait, Neuropsychiatry Department, Faculty of Medicine, Minia University, Egypt, 3Neurology Division, Mubarak Alkabeer hospital, Kuwait, 4Head of Pharmacy Department, Ibn Sina hospital, Kuwait 5Merck…

Primary Results of NOVA: A Randomized Controlled Study of the Efficacy of 6 Week Dosing of Natalizumab Versus Continued 4-Week Treatment for Multiple Sclerosis

1John Foley, 2Gilles Defer, 3Lana Zhovtis Ryerson, 4Jeffrey A. Cohen, 5Douglas L. Arnold, 6Helmut Butzkueven, 7Gary Cutter, 8Gavin Giovannoni, 9Joep Killestein, 10Heinz Wiendl, 11Karen Smirnakis,11Shan Xiao,11George Kong,12Robert Kuhelj,11Nolan Campbell 1Rocky Mountain MS Clinic, Salt Lake City, United States; 2Department of Neurology, Centre Hospitalier Universitaire de Caen, Caen, France; 3Department of Neurology, NYU Langone Health, New…